Author Details

Bakulev, A. L.

Issue Section Title File
Vol 90, No 1 (2014) DRUG TREATMENT IN DERMATOVENEROLOGY Long-term therapy of severe acne: selection of doses and administration schemes for systemic isotretinoin PDF
(Rus)
Vol 90, No 4 (2014) CLINICAL CASE REPORTS A case of a combination of Crocker - Adamson follicular spinulosa, lichen acuminatus and Little - Lassueur syndrome PDF
(Rus)
Vol 91, No 1 (2015) ORIGINAL STUDIES Endothelial dysfunction and its treatment in psoriasis patients PDF
(Rus)
Vol 91, No 1 (2015) DRUG TREATMENT IN DERMATOVENEROLOGY Microbial eczema: up-to-date topical treatment with silver sulfathiazole PDF
(Rus)
Vol 92, No 3 (2016) CLINICAL CASE REPORTS A case of localized bullous scleroderma PDF
(Rus)
Vol 92, No 3 (2016) DRUG TREATMENT IN DERMATOVENEROLOGY Using clobetasol propionate in the form of a shampoo for the treatment of patients suffering from psoriasis localized in the scalp area PDF
(Rus)
Vol 92, No 5 (2016) CLINICAL PRACTICE GUIDELINES Strategy “treat to target” for patients with psoriasis. Relevant issues to biological therapy persistence PDF
(Rus)
Vol 92, No 5 (2016) DRUG TREATMENT IN DERMATOVENEROLOGY Selective intracellular inhibition of signalling pathways - new direction in systematic treatment of psoriasis patients PDF
(Rus)
Vol 93, No 1 (2017) ORIGINAL STUDIES Methotrexate: Revisited efficiency and safety of drug administration in psoriasis patients PDF
(Rus)
Vol 93, No 5 (2017) ORIGINAL STUDIES Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis PDF
(Rus)
Vol 94, No 3 (2018) DRUG TREATMENT IN DERMATOVENEROLOGY Psoriasis: clinical and epidemiological features and therapy issues PDF
(Rus)
Vol 94, No 5 (2018) REVIEWS Evolution of the understanding of psoriasis and therapeutic approaches used to manage such patients. BCD-085 is the first Russian genetically-engineered biological preparation for the treatment of patients suffering from psoriasis PDF
(Rus)
Vol 95, No 2 (2019) ORIGINAL STUDIES Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis PDF
(Rus)
Vol 95, No 3 (2019) DRUG TREATMENT IN DERMATOVENEROLOGY Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext PDF
(Rus)
Vol 95, No 4 (2019) CLINICAL PRACTICE GUIDELINES Dermatoscopy in the diagnosis of pigmented nevi PDF
(Rus)
Vol 95, No 4 (2019) DRUG TREATMENT IN DERMATOVENEROLOGY Results of the long-term observational noninterventional prospective study BODYGUARD in psoriasis patients PDF
(Rus)
Vol 95, No 5 (2019) DRUG TREATMENT IN DERMATOVENEROLOGY Certolizumab pegol: new opportunities for treatment of moderate to severe plaque psoriasis PDF
(Rus)
Vol 97, No 5 (2021) REVIEWS Revisiting the question of psoriasis classification PDF
(Rus)

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies